FAKTOR-OPTIONSSCHEIN - BB BIOTECH N Stock

Certificat

DE000SU6EHK6

Delayed Deutsche Boerse AG 07:29:27 2024-05-23 am EDT
9.03 EUR -0.55% Intraday chart for FAKTOR-OPTIONSSCHEIN - BB BIOTECH N
Current month-0.87%
1 month-2.37%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-23 9.03 -0.55%
24-05-22 9.08 -1.09%
24-05-21 9.18 +1.55%
24-05-20 9.04 +0.11%
24-05-17 9.03 +0.11%

Delayed Quote Deutsche Boerse AG

Last update May 23, 2024 at 07:29 am EDT

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying BB BIOTECH AG
IssuerLogo Issuer Société Générale Société Générale
WKN SU6EHK
ISINDE000SU6EHK6
Date issued 2024-01-02
Strike 41.9 CHF
Maturity Unlimited
Parity 1 : 1
Emission price 10.06
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 9.99
Lowest since issue 8.29
Spread 0.03
Spread %0.33%

Company Profile

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Sector
-
More about the company

Ratings for BB Biotech AG

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BB Biotech AG

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
41.05 CHF
Average target price
47.7 CHF
Spread / Average Target
+16.20%
Consensus